XULANE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XULANE (XULANE).
Ethinyl estradiol and norelgestromin (the active metabolites of norgestimate) suppress gonadotropin release, inhibiting ovulation and increasing cervical mucus viscosity, impairing sperm penetration.
| Metabolism | Ethinyl estradiol is metabolized primarily via CYP3A4; norgestimate is metabolized to the active metabolite norelgestromin by first-pass hepatic metabolism and further metabolized by CYP3A4 and CYP2C19. |
| Excretion | Primarily renal (approximately 60-70% as unchanged drug), with biliary/fecal elimination accounting for 20-30%. |
| Half-life | Terminal elimination half-life is 4.5 hours; in severe renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 12-15 hours, requiring dose adjustment. |
| Protein binding | Approximately 85-90% bound to serum albumin; binding is saturable at high concentrations. |
| Volume of Distribution | Volume of distribution is 0.9-1.2 L/kg, indicating extensive distribution into total body water and some tissue binding. |
| Bioavailability | Oral bioavailability is 65-75% due to first-pass metabolism; food reduces absorption by 15-20%. |
| Onset of Action | Oral: 30-60 minutes; intravenous: within minutes; clinical effect peaks at 1-2 hours. |
| Duration of Action | Duration is 6-8 hours for oral administration; intravenous duration is 4-6 hours. Clinical effect correlates with plasma concentrations above 0.1 mcg/mL. |
Apply 1 patch (20 cm² containing 600 mcg ethinyl estradiol and 6 mg norelgestromin) transdermally once weekly for 3 weeks, followed by 1 patch-free week.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No formal studies; use caution in patients with renal impairment, especially if GFR <30 mL/min, as systemic exposure may increase; consider alternative contraception. |
| Liver impairment | Contraindicated in patients with Child-Pugh Class B or C hepatic impairment; no dose adjustment for mild (Child-Pugh A) disease, but use with caution. |
| Pediatric use | Not approved for use before menarche; post-menarche adolescents: same dosing as adults (1 patch weekly for 3 weeks, then 1 week off). |
| Geriatric use | Not indicated for use in postmenopausal women; no specific geriatric studies, but use is generally not appropriate in this population. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for XULANE (XULANE).
| Breastfeeding | XULANE is excreted in breast milk with an milk-to-plasma ratio (M/P) of approximately 0.4. Small amounts are transferred to the infant, and exposure is unlikely to cause adverse effects. However, it may reduce milk production and should be used with caution in lactating women, especially during the early postpartum period. |
| Teratogenic Risk | XULANE (etonogestrel contraceptive implant) is contraindicated during pregnancy. First trimester: Use during organogenesis may cause a slight increased risk of cardiovascular defects and neural tube defects, though large studies show no major teratogenicity. Second/third trimester: No specific fetal risks from etonogestrel alone; however, progestins may alter placental function and should be avoided. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day). Women over 35 who smoke should not use this product.
| Serious Effects |
["Thrombophlebitis or thromboembolic disorders (current or history)","History of deep vein thrombosis or pulmonary embolism","Cerebrovascular or coronary artery disease (current or history)","Valvular heart disease with complications","Uncontrolled hypertension","Diabetes with vascular involvement","Headaches with focal neurological symptoms (e.g., migraine with aura) especially if age >35","Major surgery with prolonged immobilization","Known or suspected carcinoma of the breast or endometrium","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or with prior pill use","Hepatic adenomas or carcinomas (current or history)","Known or suspected pregnancy","Hypersensitivity to any component","Cigarette smoking in women over 35"]
| Precautions | ["Increased risk of thromboembolic events (e.g., VTE, arterial thrombosis) especially in smokers >35 years","Increased risk of myocardial infarction and stroke","Hepatic neoplasia and liver disease","Hypertension (worsening or new onset)","Gallbladder disease","Carbohydrate and lipid metabolic effects","Headache (including migraine)","Bleeding irregularities (spotting, breakthrough bleeding, amenorrhea)","Depression","Hereditary angioedema","Chloasma (may persist)","Jaundice or liver function abnormalities","Interaction with anticonvulsants and other drugs decreasing efficacy"] |
Loading safety data…
| Fetal Monitoring | Monitor for pregnancy prior to insertion and exclude pregnancy if implant is overdue for replacement. During use, monitor for signs of pregnancy (e.g., missed menses, unusual bleeding). If pregnancy occurs, remove implant promptly. No routine fetal monitoring required otherwise. |
| Fertility Effects | XULANE provides highly effective reversible contraception. After removal, fertility returns rapidly; median time to ovulation is 3-4 weeks. No long-term adverse effects on fertility. In women with pre-existing menstrual irregularities, return to baseline cycle may take several months. |